Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Search History:
Count: 279
Selected: 0
NCT IDTitle
NCT03570021ESTIMation of the ABiLity of Prophylactic Central Compartment Neck Dissection to Modify Outcomes in Low-risk Differentiated Thyroid Cancer
NCT05071001Long Term Brain Toxicity of Chemotherapy in Patients Treated for a Bone TumorDuring Childhood or Adolescence
NCT00910728Study to Assess the Safety of AZD1480 in Patients With Myeloproliferative Diseases
NCT06479057PROACT is a Prospective Master Protocol for a Cohort Study Focused on Evaluating the Implementation of Integrated Proactive Supportive Care Pathways at Gustave Roussy
NCT02008734Randomized Phase II Study to Assess PD 0332991 in Breast Cancer
NCT06642844Bevacizumab-based Chemotherapy Adapted to Bevacizumab Pharmacokinetics in 1st-line Treatment
NCT01516580Intergroup Randomized Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Rituximab Evaluation in High Risk Patients
NCT05912075Preoperative Radiotherapy And ASTX660 in Rectum Cancer
NCT00349505Intraperitoneal Hyperthermic Chemotherapy in Epithelial Ovarian Carcinoma
NCT00949039Study Comparing Isolated Pelvic Perfusion With TNF-α 0.3 mg and Melphalan 1.5 mg/kg Versus Standard Treatment in Patients With Non Resectable, Recurrent Gynaecologic or Digestive Pelvic Cancer
NCT03314324A Study of Patient Preference Between ODM-201 and Enzalutamide in Men With Metastatic Castrate-resistant Prostate Cancer
NCT05705791Clinical Investigation Evaluating Safety and Efficacy of Selective Intra-arterial 166Holmium Radiation Therapy in Combination With Atezolizumab and Bevacizumab for Non Resectable Hepatocellular Carcinoma
NCT06298084Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd
NCT04274868Pediatric Hepatic Tumors
NCT05705687Validation of a Treatment Algorithm for Poor-Risk NSGCTnon Seminomatous Germ-cell Tumors
NCT02063009Measurement of Cardiac Index Using an Implanted Central Venous Access Port in Patients Scheduled for Oncologic High-risk Surgery
NCT01557114Study of Radiotherapy Administered in Combination With Ipilimumab in Patients With Unresectable Stage III or Stage IV Advanced Malignant Melanoma
NCT04775121Classical Monocyte Kinetics in Chronic Myelomonocytic Leukemia
NCT05890781Engineering Immune Organoids to Study Pediatric Cancer
NCT03609112Neurocognitive Risks in Children With Solid Tumors
NCT03212469A Trial of Durvalumab and Tremelimumab in Combination With SBRT in Patients With Metastatic Cancer
NCT00147160Phase II Cisplatin + Temozolomide in Malignant Glial Tumours in Children and Adolescents
NCT00126230Trial of Docetaxel-Samarium in Patients With Hormone-Refractory Advanced Prostate Cancer
NCT03244956Efficacy of MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid Cancer
NCT00005062Radiation Therapy in Patients With Limited-Stage Small Cell Lung Cancer in Complete Remission
NCT02516774A Trial of Adalimumab Combined to Chemotherapy and Radiotherapy in Patients With Anaplastic Thyroid Cancers
NCT00180947Study of Vinorelbine and Cyclofosfamide Among Patients With Refractory Tumours or in Relapse
NCT06007092Therapeutic Vaccine in Patients With Human Papillomavirus HPV-positive Oropharyngeal Cancer
NCT02992912Atezolizumab With Stereotactic Ablative Radiotherapy in Patients With Metastatic Tumours
NCT02517125Evaluation of the Contribution of Transoral Robotic-assisted Surgery Using Da Vinci Xi for Head and Neck Tumors
NCT00126269Trial Comparing Cisplatin With or Without Gemcitabine in Patients With Carcinoma of Unknown Primary
NCT06505590STEpwise Research Program to Promote INGeniouS ONline Supportive Solutions in the Relief of Cancer-related Fatigue
NCT03366480A Study to Assess the Efficacy and Safety of ABTL0812
NCT00162721The Addition of Polychemotherapy to Adjuvant Radiotherapy in the Treatment of Non-Metastatic Uterine Sarcomas
NCT01289522Chemotherapy With Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
NCT01701479Long Term Continuous Infusion ch14.18/CHO Plus s.c. Aldesleukin (IL-2)
NCT03155386Optimized Angiomammography and Comparison With Standard Angiomammography
NCT00552149Biliary Cancers: EGFR INhibitor, Gemcitabine and Oxaliplatin
NCT02994576Atezolizumab as Induction Therapy in Non-small Cell Lung Cancer
NCT00181025Isolated Pelvic and Limb Perfusion in the Treatment of Locally Advanced Sarcoma of Pelvis and Limbs' Girdle
NCT00127049Trial of Gemcitabine, Cisplatin, and Ifosfamide in Patients With Relapsed Non-Seminomatous Germ-Cell Tumors
NCT00346645A Phase II Study of Velcade® in Patients Stage IIIB OR IV Non-Small Cell Lung Cancer
NCT02089100Trial of Superiority of Stereotactic Body Radiation Therapy in Patients With Breast Cancer
NCT04826432Pasireotide to Reduce Clinically Relevant Digestive Leakage After Complete Cytoreductive Surgery (CRS) Plus Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) for Peritoneal Carcinomatosis
NCT01715363Feasibility of an Immediate Preoperative Chemotherapy Before Resection fo Colorectal Cancer
NCT02260739Sequential Analysis in Patients With an Hemopathy
NCT03984318Predictive Markers of Immune-related Adverse Events in Patients Treated With Immune Stimulatory Drugs
NCT00180791High Risk Primitive Neuroectodermal (PNET) Brain Tumors in Childhood
NCT01834950Identification of Early Markers of Response and Resistance to Trastuzumab
NCT07016230Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocrine Carcinomas (NECs), With Biomarker Analysis to Characterize Response/Resistance (UNLOCK TARLATAMAB)